Early research (1974–1999)

📚 = systematic review / meta-analysis      🧬 = genetics focus      🐀 = animal study

Jump to:
1998 | 1996 | 1994 | 1992 | 1990 | 1980s | 1970s
2011–present | 2000–2010

1999

↑ back to top

Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1999;54(4):670-678. doi:10.1016/s0090-4295(99)00209-5

Cather JC, Lane D, Heaphy MR Jr, Nelson BR. Finasteride–an update and review. Cutis. 1999 Sep;64(3):167-72 | PubMed

Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999;41(4):550‐554. doi:10.1016/S0190-9622(99)80051-6 | PubMed

Frankel S. Study of the Food and Drug Administration files on Propecia: dosages, side effects, and recommendations. Arch Dermatol. 1999;135(3):257‐258. doi:10.1001/archderm.135.3.257 | PubMed

[Comment] Kaufman KD. Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. Arch Dermatol. 1999;135(8):989‐990. doi:10.1001/archderm.135.8.989 | PubMed

[Comment] Roberts JL. Finasteride in a 1-mg dose is safe and effective. Arch Dermatol. 1999;135(8):990. doi:10.1001/archderm.135.8.990 | PubMed

Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology. 1999;53(4):690-695. doi:10.1016/s0090-4295(98)00666-9

🐀 Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther. 1999 Feb;288(2):679-84. | PubMed | Journal site

Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):930–7. doi:10.1016/s0190-9622(99)70081-2 | PubMed

McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111-126. doi:10.2165/00003495-199957010-00014

Overstreet JW, Fuh VL, Gould J, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 1999;162(4):1295–1300. PubMed

[Comment] Freidlin V, Ko HS, Wilkin JK. Re: chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 2000;164(4):1319–1320. PubMed

Rhodes PR, Krogh RH, Bruskewitz RC. Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology. 1999;53(6):1090-1098. doi:10.1016/s0090-4295(99)00041-2

Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555–563. doi:10.1016/S0190-9622(99)80052-8 | PubMed

1998

↑ back to top

Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol. 1998;34(3):169-175. doi:10.1159/000019706

Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther. 1998;64(6):636–647. doi:10.1016/S0009-9236(98)90054-6 | PubMed

🐀 Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res. 1998;58(2):215-218. PubMed

🐀 Kamolpatana K, Johnston SD, Hardy SK, Castner S. Effect of finasteride on serum concentrations of dihydrotestosterone and testosterone in three clinically normal sexually intact adult male dogs. Am J Vet Res. 1998;59(6):762-764. PubMed

Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. doi:10.1016/S0190-9622(98)70007-6

Uygur MC, Arik AI, Altuğ U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids. 1998;63(4):208-213. doi:10.1016/s0039-128x(98)00005-1

Uygur MC, Gür E, Arik AI, Altuğ U, Erol D. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia. 1998;30(1):5-10. doi:10.1111/j.1439-0272.1998.tb01375.x

1997

↑ back to top

Amichai B, Grunwald MH, Sobel R. 5 alpha-reductase inhibitors–a new hope in dermatology? Int J Dermatol. 1997 Mar;36(3):182-4. doi:10.1046/j.1365-4362.1997.00191.x | PubMed

Carlin BI, Seftel AD, Resnick MI, Findlay J. Finasteride induced gynecomastia. J Urol. 1997 Aug;158(2):547. PubMed

Habib FK, Ross M, Tate R, Chisholm GD. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clin Endocrinol (Oxf). 1997;46(2):137–144. doi:10.1046/j.1365-2265.1997.950908.x

🐀 Iguer-Ouada M, Verstegen JP. Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs. J Reprod Fertil Suppl. 1997;51:139-149. https://europepmc.org/article/MED/9404280

Imperato-McGinley J. 5 alpha-reductase-2 deficiency. Curr Ther Endocrinol Metab. 1997;6:384–387. PubMed

Martínez Sarmiento M, Cuñat Albert E, López Alcina E, Pontones Moreno JL, Sanz Chinesta S, Jiménez Cruz JF. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up]. Actas Urol Esp. 1997;21(2):105-110. PubMed

🐀 Prahalada S, Tarantal AF, Harris GS, et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology. 1997;55(2):119-131. doi:10.1002/(SICI)1096-9926(199702)55:2<119::AID-TERA1>3.0.CO;2-Z

Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther. 1997;19(2):243-258. doi:10.1016/s0149-2918(97)80113-0

1996

↑ back to top

Chueh SC, Yu HJ, Chiu TY, Huang CY, Lai MK. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience. J Formos Med Assoc. 1996;95(8):650-652. PubMed

Fleshner NE, Fair WR. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 1996;78(6):907-910. doi:10.1046/j.1464-410x.1996.29918.x

Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. Prostate. 1996;29(2):83-90. doi:10.1002/(SICI)1097-0045(199608)29:2<83::AID-PROS3>3.0.CO;2-I

[Correspondence] Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med. 1996 Sep 12;335(11):823. doi:10.1056/NEJM199609123351116 | PubMed

Hill M, Petrik R, Hampl R, Stárka L. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment. Horm Metab Res. 1996;28(10):562-564. doi:10.1055/s-2007-979853 | PubMed

Kaplan SA, Olsson CA. Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia. Clin Ther. 1996;18(1):73–83. doi:10.1016/s0149-2918(96)80180-9 | PubMed

Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335(8):533-539. doi:10.1056/NEJM199608223350801

Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ. 1996;155(9):1251-1259. PubMed

Pytel’ IA, Vinarov AZ. [Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia]. Urol Nefrol (Mosk). 1996;(4):25-27. PubMed

Rittmaster RS, Norman RW, Thomas LN, Rowden G. Evidence for atrophy and apoptosis in the prostates of men given finasteride. J Clin Endocrinol Metab. 1996;81(2):814–819. doi:10.1210/jcem.81.2.8636309 | PubMed

Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16-27. doi:10.2165/00003088-199630010-00002

Tian G. In vivo time-dependent inhibition of human steroid 5 alpha-reductase by finasteride. J Pharm Sci. 1996;85(1):106–111. doi:10.1021/js950100g | PubMed

Tveter KJ, Beisland HO, Andersen JT, et al. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study]. Tidsskr Nor Laegeforen. 1996;116(27):3226-3230. PubMed

🐀 Wright AS, Thomas LN, Douglas RC, Lazier CB, Rittmaster RS. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest. 1996;98(11):2558–2563. doi:10.1172/JCI119074 | PubMed

1995

↑ back to top

Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. Clin Ther. 1995;17(5):956-969. doi:10.1016/0149-2918(95)80073-5

Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab. 1995;80(6):1934-1940. doi:10.1210/jcem.80.6.7775644

Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. 1995;154(5):1642-1645; discussion 1645-6. PubMed

Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol. 1995;27(4):267-273. doi:10.1159/000475179

📚 Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother. 1995;49(7-8):319-324. doi:10.1016/0753-3322(96)82658-8

McConnell JD. Benign prostatic hyperplasia. Hormonal treatment. Urol Clin North Am. 1995;22(2):387-400. PubMed

McConnell JD, Goldwasser B, Marberger M. BPH: what really works? Contemp Urol. 1995 Apr;7(4):76-80, 82, 84 passim. PubMed

Moore E, Bracken B, Bremner W, et al. Proscar: five-year experience. Eur Urol. 1995;28(4):304-309. doi:10.1159/000475071

🐀 Rittmaster RS, Manning AP, Wright AS, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995;136(2):741–748. doi:10.1210/endo.136.2.7835306 | PubMed

Wu TT, Lee YH, Jiaan BP, Huang JK. The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. Zhonghua Yi Xue Za Zhi (Taipei). 1995;56(6):399-403. PubMed

1994

↑ back to top

🐀 Laroque PA, Prahalada S, Gordon LR, et al. Effects of chronic oral administration of a selective 5 alpha-reductase inhibitor, finasteride, on the dog prostate. Prostate. 1994;24(2):93–100. doi:10.1002/pros.2990240207

Maffei C, Fossati A, Rinaldi F, Riva E. Personality disorders and psychopathologic symptoms in patients with androgenetic alopecia. Arch Dermatol. 1994;130(7):868–872. PubMed

🐀 Prahalada S, Majka JA, Soper KA, et al. Leydig cell hyperplasia and adenomas in mice treated with finasteride, a 5 alpha-reductase inhibitor: a possible mechanism. Fundam Appl Toxicol. 1994;22(2):211-219. doi:10.1006/faat.1994.1025 | PubMed

Rittmaster RS. Finasteride. N Engl J Med. 1994;330(2):120–125. doi:10.1056/NEJM199401133300208 | PubMed

Rittmaster RS, Antonian L, New MI, Stoner E. Effect of finasteride on adrenal steroidogenesis in men. J Androl. 1994;15(4):298–301. doi:10.1002/j.1939-4640.1994.tb00453.x | PubMed

1993

↑ back to top

Fleshner NE, Trachtenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. Eur Urol. 1993;24(Suppl 2):106-12. doi:10.1159/000474400 | PubMed

🐀 Lephart ED, Husmann DA. Altered brain and pituitary androgen metabolism by prenatal, perinatal or pre- and postnatal finasteride, flutamide or dihydrotestosterone treatment in juvenile male rats. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(6):991-1003. doi:10.1016/0278-5846(93)90026-o | PubMed

Peters DH, Sorkin EM. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs. 1993;46(1):177-208. doi:10.2165/00003495-199346010-00010 | PubMed

Steiner JF. Finasteride: a 5 alpha-reductase inhibitor. Clin Pharm. 1993;12(1):15-23. PubMed

Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy, 1993;13(4):309-25; discussion 325-9. doi:10.1002/j.1875-9114.1993.tb02739.x | PubMed

1992

↑ back to top

Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185-1191. doi:10.1056/NEJM199210223271701 | PubMed

[Comment] Blumenstein BA. Finasteride for benign prostatic hyperplasia. N Engl J Med. 1993;328(6):443. PubMed

📚 Hasinski S, Miller JL, Rose LI. Finasteride for benign prostatic hyperplasia. Am Fam Physician. 1992 Nov;46(5):1511-4. PubMed

[Comment] Anand A. Thoughts on finasteride for benign prostatic hyperplasia. Am Fam Physician. 1993 Sep 15;48(4):582, 588. PubMed

1991

↑ back to top

🐀 Cukierski MA, Sina JL, Prahalada S, et al. Decreased fertility in male rats administered the 5 alpha-reductase inhibitor, finasteride, is due to deficits in copulatory plug formation. Reprod Toxicol. 1991;5(4):353-362. doi:10.1016/0890-6238(91)90094-v

🐀 Rittmaster RS, Magor KE, Manning AP, Norman RW, Lazier CB. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Mol Endocrinol. 1991;5(7):1023–1029. doi:10.1210/mend-5-7-1023 | PubMed

Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol. 1991;20 Suppl 1:82-86. doi:10.1159/000471752 | PubMed

🐀 Wise LD, Minsker DH, Cukierski MA, et al. Reversible decreases of fertility in male Sprague-Dawley rats treated orally with finasteride, a 5 alpha-reductase inhibitor. Reprod Toxicol. 1991;5(4):337-346. doi:10.1016/0890-6238(91)90092-t

1990

↑ back to top

Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 1990;70(4):1136–1141. doi:10.1210/jcem-70-4-1136 | PubMed

Imperato-McGinley J, Shackleton C, Orlic S, Stoner E. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. J Clin Endocrinol Metab. 1990;70(3):777-782. doi:10.1210/jcem-70-3-777 | PubMed

McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1990;17(3):661-670. PubMed

Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990;37(3):375–378. doi:10.1016/0960-0760(90)90487-6 | PubMed

1980s

↑ back to top

🐀 Brooks JR, Baptista EM, Berman C, et al. Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor. Endocrinology. 1981;109(3):830‐836. doi:10.1210/endo-109-3-830 | PubMed

🐀 Brooks JR, Berman C, Hichens M, Primka RL, Reynolds GF, Rasmusson GH. Biological activities of a new steroidal inhibitor of delta 4-5 alpha-reductase. Proc Soc Exp Biol Med. 1982;169(1):67-73. PubMed

🐀 Erskine MS. Effects of an anti-androgen and 5 alpha-reductase inhibitors on estrus duration in the cycling female rat. Physiol Behav. 1983;30(4):519-524. doi:10.1016/0031-9384(83)90214-7 | PubMed

🐀 George FW, Johnson L, Wilson JD. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. Endocrinology. 1989;125(5):2434-2438. doi:10.1210/endo-125-5-2434 | PubMed

🐀 Imperato-McGinley J, Binienda Z, Arthur A, Mininberg DT, Vaughan ED Jr, Quimby FW. The development of a male pseudohermaphroditic rat using an inhibitor of the enzyme 5 alpha-reductase. Endocrinology. 1985;116(2):807‐812. doi:10.1210/endo-116-2-807 | PubMed

🐀 Kadohama N, Wakisaka M, Kim U, Karr JP, Murphy GP, Sandberg AA. Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5 alpha-reductase. J Natl Cancer Inst. 1985;74(2):475-486. PubMed

Liang T, Rasmusson GH, Brooks JR. 12. Androgens: Pharmacodynamics and antagonists. Biochemical and biological studies with 4-aza-steroidal 5 alpha-reductase inhibitors. J Steroid Biochem. 1983;19(1A):385‐390. doi:10.1016/s0022-4731(83)80051-x | PubMed

🐀 Wenderoth UK, George FW, Wilson JD. The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology. 1983;113(2):569-573. doi:10.1210/endo-113-2-569 | PubMed

1970s

↑ back to top

Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213‐1215. doi:10.1126/science.186.4170.1213 | PubMed